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Edited by Peter Tontonoz and Laszlo NagyAbstract Obesity-induced chronic inﬂammation is a key com-
ponent in the pathogenesis of insulin resistance and the Meta-
bolic syndrome. In this review, we focus on the interconnection
between obesity, inﬂammation and insulin resistance. Pro-
inﬂammatory cytokines can cause insulin resistance in adipose
tissue, skeletal muscle and liver by inhibiting insulin signal trans-
duction. The sources of cytokines in insulin resistant states are
the insulin target tissue themselves, primarily fat and liver, but
to a larger extent the activated tissue resident macrophages.
While the initiating factors of this inﬂammatory response remain
to be fully determined, chronic inﬂammation in these tissues
could cause localized insulin resistance via autocrine/paracrine
cytokine signaling and systemic insulin resistance via endocrine
cytokine signaling all of which contribute to the abnormal meta-
bolic state.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Macrophage1. Insulin resistance and human disease
Insulin resistance is a characteristic feature of most patients
with type 2 diabetes mellitus (T2DM) and is one of the deﬁning
clinical features in the metabolic syndrome (MetS) or syn-
drome X. MetS is a constellation of biochemical and physical
derangements which can also include central obesity, athero-
genic dyslipidemia (low HDL-C, elevated LDL-C and serum
triglycerides), a prothrombotic state, a pro-inﬂammatory state
and hypertension. The prevalence of MetS among adults 20
years or older is 23.7% in the United States according to the
Third National Health and Nutrition Examination Survey
(NHANES III). This would indicate that approximately 47Abbreviations: T2DM, type 2 diabetes mellitus; MetS, metabolic
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doi:10.1016/j.febslet.2007.11.057million Americans suﬀer from MetS when extrapolated to
the 2000 US census data. As the epidemic of obesity shows
no signs of reversing, this number is likely to rise dramatically
in the future [1]. In the past, this syndrome has often been con-
sidered a disease associated with adulthood, but a recent epide-
miologic study indicates that in the past decade there has been
a 50% increase in the prevalence of MetS in adolescents [2].
While the clinical deﬁnition of MetS may vary between deﬁn-
ing agencies, i.e. the World Health Organization (WHO), the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III), and The International Diabetes
Federation (IDF) the existence of it is indisputable and
understanding its etiology is of high importance.2. Insulin signaling
Insulin is a pleiotropic hormone which has diverse functions
including stimulation of nutrient transport into cells, regula-
tion of gene expression, modiﬁcation of enzymatic activity
and regulation of energy homeostasis via actions in the arcuate
nucleus (reviewed in [3,4]). These functions of insulin are ex-
erted across a variety of insulin target tissues through several
intracellular signaling cascades. The main focus of this review
with regard to insulin action will be glucose metabolism in the
insulin target tissues: liver, adipose tissue and skeletal muscle.
In skeletal muscle insulin promotes glucose uptake by stimu-
lating translocation of the GLUT4 glucose transporter to the
plasma membrane, and impaired skeletal muscle insulin signal-
ing results in decreased glucose disposal. In the liver, insulin
inhibits the expression of key gluconeogenic enzymes and,
therefore, insulin resistance in liver leads to elevated hepatic
glucose production. Adipose tissue insulin signaling results in
decreased hormone sensitive lipase activity and this anti-lipo-
lytic eﬀect inhibits free fatty acid (FFA) eﬄux out of adipo-
cytes. Increased circulating FFA can result in decreased
insulin sensitivity in skeletal muscle due to an increase in intra-
cellular lipid products, including fatty acyl-CoA and ceramide
[5–7]. These lipid intermediates can activate the serine/threo-
nine kinase, protein kinase C-h (PKCh), which then inhibits
the insulin signaling cascade. Perturbations in glucose metabo-
lism due to insulin resistance are further exacerbated when
insulin production is compromised, as in patients with T2DM.2.1. Insulin receptor substrate (IRS)-mediated insulin signaling
Insulin signaling involves a complex signaling cascade down-
stream of the insulin receptor. This signaling cascade branchesblished by Elsevier B.V. All rights reserved.
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3-kinase (PI3K)-AKT (also called protein kinase B (PKB))
pathway which is largely responsible for insulin action on glu-
cose uptake, as well as other metabolic actions of insulin,
including the suppression of gluconeogenesis. The second
pathway is the Ras-mitogen activated protein kinase (MAPK)
pathway which mediates gene expression, but also interacts
with the PI3K-AKT pathway to control cell growth and diﬀer-
entiation (reviewed in [8]). The common intermediate to these
pathways is IRS, which include four distinct family members,
IRS1-4. For the purpose of this review, we will focus on IRS1,
as defects in insulin signaling typically involve this IRS. Acti-
vation of the insulin receptor leads to tyrosine phosphorylation
of IRS1 thereby initiating signal transduction. When IRS1 is
alternatively phosphorylated on serine 307, its downstream sig-
naling ability is diminished [9]. Serine kinases that phosphory-
late serine 307 include I kappa B kinase beta (Ikkb) in the
NFjB pathway and C-jun N-terminal kinase 1 (Jnk1) in the
JNK/AP-1 pathway. Additional inﬂammation-related negative
regulators of IRS proteins include the suppressor of cytokine
signaling (Socs). Socs1 and Socs3, which are induced in inﬂam-
mation, promote the ubiquitylation and subsequent degrada-
tion of IRS proteins [10] (Fig. 1).
2.2. Non-IRS-mediated insulin signaling
Several other substrates for mediating insulin action, in
addition to IRS1-4, have been described. The activated insulin
receptor can phosphorylate tyrosine residues on Src homology
2 containing protein (Shc) which then binds to the Son of sev-
enless (SOS)-growth factor receptor-bound protein 2 (Grb2)Fig. 1. Direct interaction of insulin signaling and inﬂammatory pathways.
PI3K/AKT pathway mediates insulin action on nutrient metabolism includin
gene expression, but also interacts with the PI3K-AKT pathway to control ce
tyrosine phosphorylation of IRS1 thereby initiating signal transduction. Stim
in the activation of the serine kinases, Ikkb and Jnk1, which reduce the signali
of IRS proteins include the Socs proteins and NO, which are induced in inﬂ
activity by s-nitrosylation of Akt.complex which then triggers the Ras-MAPK signaling cascade
(reviewed in [8]). An additional mediator of insulin action is
the heterotrimeric G protein, Gaq/11. Phosphorylation of
Gaq/11 by the insulin receptor activates PI3K, thus, stimulat-
ing GLUT4-mediated glucose uptake. This signaling pathway
is inhibited by G-protein-coupled receptor kinase-2 (Grk2)
which binds and inhibits the Ga subunit of Gaq/11 [11,12].
Finally, the proto-oncogene product, Cbl, is recruited to the
insulin receptor by the adapter protein Cbl associated protein
(CAP) and the CAP/Cbl complex can mediate cell surface
translocation of GLUT4 independent of PI3K activity [13].
2.3. Inﬂammation and insulin signaling
As early as 1950s, there was epidemiological evidence sug-
gesting a correlation between inﬂammation and insulin resis-
tant states such as obesity, but the mechanistic links were
unknown. In the last decade, however, it has become increas-
ingly evident that obesity and the concomitant development of
inﬂammation are major components of insulin resistance.
Studies in human obesity and insulin resistance have revealed
a clear association between the chronic activation of pro-
inﬂammatory signaling pathways and decreased insulin sensi-
tivity. For example, elevated levels of tumor necrosis factor-
a (TNF-a), interleukin-6 (IL-6) and interleukin (IL-8) have
all been reported in various diabetic and insulin resistant states
[14–18]. In addition, the inﬂammatory marker C-reactive pro-
tein (CRP), a non-speciﬁc acute phase reactant, is commonly
elevated in human insulin resistant states [19]. Also, experi-
ments in naturally occurring rodent models of obesity, knock-
out and transgenic mice, as well as detailed studies of insulinThe insulin signaling cascade branches into two main pathways. The
g glucose uptake. The Ras/MAPK pathway mediates insulins eﬀect on
ll growth and diﬀerentiation. Activation of the insulin receptor leads to
ulation of the NFjB and AP-1 Fos/Jun inﬂammatory pathways results
ng ability of IRS1. Additional inﬂammation-related negative regulators
ammation, and promote IRS degradation. NO also reduces PI3K/Akt
Fig. 2. Obesity and the development of inﬂammation and insulin resistance. Obesity-induced changes in skeletal muscle, adipose tissue and the liver
result in localized inﬂammation and insulin resistance (IR) through autocrine and paracrine signaling. Endocrine-mediated cross-talk between insulin
target tissues contributes to insulin resistance in distant tissues. Systemic inﬂammation and insulin resistance are the net eﬀect of these changes.
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mechanistic links between obesity-induced inﬂammation and
insulin resistant states (see Fig. 2).
2.4. The initiation of inﬂammation in obesity
The precise physiological events leading to the initiation of
the inﬂammatory response in obesity remain incompletely
understood. One theory holds that the expansion of adipose
tissue leads to adipocyte hypertrophy and hyperplasia and that
large adipocytes outstrip the local oxygen supply leading to
cell autonomous hypoxia with activation of cellular stress
pathways. This causes cell autonomous inﬂammation and the
release of cytokines and other pro-inﬂammatory signals.
Adipokines such as resistin, leptin and adiponectin, which
are secreted by adipocytes, can also aﬀect inﬂammation and
insulin sensitivity. As part of the chronic inﬂammatory pro-
cess, locally secreted chemokines attract pro-inﬂammatory
macrophages into the adipose tissue where they form crown-
like structures around large dead or dying adipocytes. These
tissue macrophages then release cytokines that further activate
the inﬂammatory program in neighboring adipocytes, exacer-
bating inﬂammation and insulin resistance. Hepatic inﬂamma-
tion can also occur in obesity whereby inﬂammatory pathway
activation could be the result of steatosis and/or increased
hepatocyte stress pathway responses. This can result in hepato-
cyte-autonomous inﬂammation. Kupﬀer cells (liver-resident
macrophage-like cells) can also become activated, releasing
locally acting cytokines which further exacerbates inﬂamma-
tion and hepatic insulin resistance. In addition, overnutrition
and obesity are often accompanied by elevations in tissue
and circulating FFA concentrations, and saturated FFAs can
directly activate pro-inﬂammatory responses in vascular endo-
thelial cells, adipocytes and myeloid-derived cells [20]. The re-sult of these obesity-induced physiologic events is the
development of systemic inﬂammation.3. The role of inﬂammation-related proteins in insulin target
tissues and the development of insulin resistance
3.1. Tumor necrosis factor-a (Tnf)
Tnf (a.k.a. Tnfa) is a pro-inﬂammatory cytokine secreted
predominantly by monocytes and macrophages and has wide
ranging biological eﬀects on lipid metabolism, coagulation
and endothelial function. Activation of the Tnf receptor results
in stimulation of NFjB signaling via Ikkb. An important early
study on the interplay between obesity, inﬂammation and insu-
lin resistance showed that Tnf expression was elevated in adi-
pose tissue isolated from diﬀerent obese rodent models.
Hotamisligil et al also showed that immuno-neutralization of
Tnf in obese fatty rats ameliorated insulin resistance [21]. Sub-
sequently, Hotamisligil et al went on to show similar correla-
tions between TNF levels, obesity and insulin resistance in
man [18]. Corresponding in vitro experiments demonstrated
that by activating Ikkb, Tnf stimulation leads to serine phos-
phorylation of Irs1 which attenuates its ability to transduce
insulin mediated cellular events [22]. Mice genetically deﬁcient
in Tnf or the Tnf receptor 1 gene (Tnfr1) do not develop insulin
resistance caused by high fat feeding or obesity [23].
Tnf can also aﬀect insulin signaling independent of IRS1.
Thus, treatment of cultured 3T3-L1 adipocytes with Tnf leads
to reduced expression of the insulin receptor, IRS1 and Glut4
genes, as well as a decrease in insulin stimulated glucose uptake
[24]. Ruan et al. also showed a Tnf-induced decrease in 3T3-L1
adipocyte genes, including GLUT4, Hormone Sensitive Lipase
(HSL), long-chain fatty acyl CoA synthetase, adiponectin
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protein-alpha (C/EBP), and the nuclear receptors Pparg
and retinoic acid x receptor (RXR). These genes all contribute
to glucose homeostasis, both directly and indirectly, and
changes in adipocyte expression of these genes likely contrib-
ute to insulin resistance in obesity induced-chronic inﬂamma-
tion [25].3.2. Jnk1 and Jnk2
Jnk1 (encoded by Mapk8) also contributes to the develop-
ment of insulin resistance in obese and diabetic states. Hiros-
umi et al. found elevated JNK activity in liver, adipose tissue
and skeletal muscle of obese insulin resistant mice, and knock-
out of Jnk1 (Jnk1/) leads to amelioration of insulin resis-
tance in high fat diet (HFD) fed mice. At the cellular level,
these workers also showed that Jnk1 knockout led to de-
creased IRS1 phospho-Ser307 in liver. Importantly, deletion
of Jnk1 also caused resistance to the development of obesity
so the improved insulin sensitivity in these animals could be
a result of decreased adiposity and/or decreased Jnk1 activity
in insulin target cells [26]. The role of Jnk2 was also assessed
in these studies and did appear to play a signiﬁcant role in
the development of obesity-induced insulin resistance. More
recent data, however, show that Jnk2 can be involved in met-
abolic regulation when Jnk1 is absent, since, Jnk1+/Jnk2/
mice phenocopy Jnk1/ mice in their reduced adiposity and
improved insulin sensitivity. This suggests functional in vivo
interactions between these isoforms in the regulation of insulin
action [27].3.3. Ikkb
The use of the anti-inﬂammatory compounds, salicylate and
its derivative aspirin, for treating symptoms of T2DM dates
back over 100 years. While they are somewhat eﬀective in
achieving glucose control at high doses, side eﬀects, such as
gastrointestinal bleeding and tinnitus, prevent their widespread
use [28]. These compounds are relatively weak inhibitors of
Ikkb, thus preventing Irs1 serine307 phosphorylation and this
presumably accounts for their insulin-sensitizing eﬀects [29].
Several approaches have been used to demonstrate Ikkbs di-
rect involvement in diet-induced chronic inﬂammation and
insulin action.
Lipid infusion causes acute insulin resistance in rodents and
Kim et al have shown that pretreatment of lipid infused rats
with salicylates improves glucose utilization in skeletal muscle
as measured during hyperinsulinemic-euglycemic clamp stud-
ies. They also performed lipid infusions in Ikkb heterozygous
knockout mice (Ikkb+/) and reported similar improvements
in insulin sensitivity when compared to wildtype controls [30].
A subsequent study by Yuan et al. showed that Tnf treat-
ment of 3T3L1 adipocytes induces insulin resistance and that
this could be prevented by pretreatment of cells with aspirin.
A parallel experiment was performed in adipocytes using oka-
daic acid to activate Ikkb independent of Tnf stimulation, and,
again, aspirin prevented okadaic acid-induced insulin resis-
tance. In vivo studies by these investigators have also demon-
strated that salicylate treatment of obese rats and mice protects
them from insulin resistance [31].
Mice transgenic for tissue speciﬁc activators and repressors
of Ikkb have been used to determine the tissue-speciﬁc contri-
bution of Ikkb to insulin resistance. Mice with a liver-speciﬁcconstitutively active Ikkb transgene (LIKK) developed hyper-
glycemia and decreased hepatic insulin sensitivity with mild
secondary systemic insulin resistance in skeletal muscle. These
mice also displayed liver expression of the pro-inﬂammatory
markers IL-6, IL-1b and Tnf similar to that found in the liver
of obese mice. In rescue experiments, LIKK mice treated with
sodium salicylate or IL-6 neutralizing antibodies had markedly
improved insulin sensitivity. In addition, mice expressing the
liver-speciﬁc IjBa super-repressor transgene (LISR), which
prevents the activation of Ikkb, protected both LIKK and ob-
ese mice from hepatic insulin resistance. Another important
ﬁnding in this study was the elevated expression of the macro-
phage speciﬁc markers, Emr1 (also known as F4/80) and Cd68,
in the livers of LIKK and obese mice. Co-expression of LISR
and LIKK in compound transgenic mice reduced both insulin
resistance and the expression of these same macrophage mark-
ers. These data indicate that hepatic inﬂammation caused by
high fat diet is mediated by both hepatocytes and Kupﬀer cells
(liver macrophages) [32]. Taken together, these studies demon-
strate the important role of Ikkb in the development of obesity
and inﬂammation-induced insulin resistance.3.4. Inducible nitric oxide synthase (iNOS)
Nitric oxide (NO) is an endogenous signaling molecule pro-
duced by nitric oxide synthase. NO acts as a signal transduc-
tion molecule for a number of physiological processes, such
as vasodilation, and is also involved in many pathophysiologic
states, including insulin resistance. Several inducers of insulin
resistance, including FFAs, pro-inﬂammatory cytokines and
oxidative stress, activate the expression of Nos2, the gene that
encodes iNOS (reviewed in [33]). In the insulin signaling path-
way, NO can reduce Akt activity by causing s-nitrosylation of
a speciﬁc cysteine residue [34]. Increased iNOS activity also re-
sults in the degradation of Irs1 in cultured skeletal muscle cells
[33]. Not surprisingly, Nos2 knockout mice are protected from
obesity-induced skeletal muscle insulin resistance, and this is
associated with improved PI3K-Akt activity [35]. In inﬂamma-
tion-induced insulin resistance, Nos2 is required for the devel-
opment of sepsis-induced skeletal muscle insulin resistance
which might also be mediated by the s-nitrosylation of the
insulin receptor, Irs1 and Akt [36,37]. Collectively, these stud-
ies highlight the possibility that increased iNOS activity plays a
direct role in the pathogenesis of insulin resistance.3.5. Interleukin-10
Il-10 is an anti-inﬂammatory cytokine produced by macro-
phages and lymphocytes. Il-10 exerts its anti-inﬂammatory
activity by inhibiting Tnf-induced NFjB activation by reduc-
ing IKK activity [38]. In human studies, it has been shown that
there is a greater incidence of insulin resistance in subjects with
reduced serum levels of IL-10 [39]. This raises the possibility
that IL-10 might exert insulin-sensitizing eﬀects. Consistent
with this idea it has been shown that mice treated with Il-10
did not become insulin resistant when treated with either Il-6
or lipid infusions [40]. Furthermore, Lumeng et al. have shown
that Il-10 treated 3T3L1 adipocytes are protected from Tnf-in-
duced cellular insulin resistance [41]. The treatment of inﬂam-
matory diseases such as psoriasis with recombinant IL-10 has
been an eﬀective therapy and therefore, modulation of Il-10
activity could serve as a potential treatment of insulin resis-
tance [42].
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ied with respect to their potential role in the development of
insulin resistance. These include Il-6 and Il-1b which are down-
stream targets of IKKb/NFkB and JNK/AP1 activation. As
such, they likely represent elements of a feed forward mecha-
nism of inﬂammation.3.6. The macrophage
A major conceptual advance in the ﬁeld of obesity-induced
inﬂammation and insulin resistance was made by the discovery
of bone marrow-derived macrophages in adipose tissue of ob-
ese mice and humans [43,44]. Weisberg et al. performed micro-
array analyses comparing adipose tissue RNA proﬁles of
various mouse models of obesity and identiﬁed a subset of
genes consistently expressed in obese mice. Further analyses
showed that this gene set, not typically expressed in adipo-
cytes, was macrophage-derived. Immunohistochemical analy-
ses conﬁrmed the source of this expression to be adipose
tissue-resident macrophages. This study showed that the per-
centage of macrophages in a given adipose tissue depot is pos-
itively correlated with adiposity and adipocyte size. They also
found that adipose tissue macrophages are responsible for
nearly all adipose tissue Tnf expression and a signiﬁcant por-
tion of Nos2 and Il6 expression. Weisberg et al. also quantiﬁed
the inﬁltration of macrophages in subcutaneous adipose tissue
from obese human subjects and reported that as high as 50% of
the total cell content consists of macrophages compared to
10% in lean controls [43]. Xu et al. reported similar ﬁndings
and also showed that thiazolidinedione (TZD) treatment could
repress the expression of macrophage-speciﬁc genes, providing
an additional mechanism by which TZD treatment improves
insulin sensitivity [44].
The discovery of adipose tissue macrophages has intro-
duced a new target tissue for potential therapies to treat insu-
lin resistance. This advance has driven the ﬁeld to examine the
importance of macrophage inﬂammatory cytokines, as well as
proteins regulating macrophage migration, tissue inﬁltration
and pathogen sensing in the development of insulin resistance.
This has been achieved by genetic manipulation in mice.
These studies have been critical to our understanding of the
relationship between insulin resistance, inﬂammation, and
obesity.3.7. Myeloid-IkkB
Initial studies of the role of macrophages in insulin signaling
showed that inhibition of the macrophage inﬂammatory path-
way protects mice from obesity-induced insulin resistance [45].
In this study, the investigators generated both a myeloid-spe-
ciﬁc deletion of Ikkb (IkkbDmye) and liver-speciﬁc deletion of
Ikkb (IkkbDhep). They found that IkkbDhep mice are protected
from HFD-induced hepatic insulin resistance, but that this
was a tissue autonomous eﬀect, since these mice still developed
insulin resistance in muscle and fat. They also showed a signif-
icant reduction in expression of inﬂammatory markers in the
liver supporting the hypothesis that inactivation of inﬂamma-
tion can prevent HFD-induced insulin resistance. Importantly,
these studies showed that tissue-speciﬁc deletion of Ikkb in
myeloid cells (IkkbDmye mice), led to systemic insulin sensitivity
with globally improved insulin action in muscle, liver and fat.
As such, these results showed that inactivation of myeloid-
Ikkb activity prevents systemic insulin resistance, most likelyby interrupting local paracrine eﬀects between resident macro-
phages and insulin target tissues [45].3.8. Ccr2/Mcp1
Monocyte chemoattractant protein-1 (Mcp-1, also known as
chemokine ligand 2 (Ccl2)) and its cognate receptor chemokine
receptor 2 (Ccr2) are also major components of insulin resis-
tance in obese mice. Mcp-1 is a chemokine secreted primarily
by macrophages and endothelial cells which promotes the
recruitment of monocytes to damaged or inﬂamed tissues.
Ccr2, the receptor for Mcp1, is expressed in monocytes but
also in the lung, spleen and thymus [46]. Weisberg et al. exam-
ined the role of Ccr2 and found that obesity-matched Ccr2/
mice displayed reduced adipose tissue macrophage inﬁltration,
reduced hepatic steatosis, decreased inﬂammatory proﬁles and
improved systemic insulin sensitivity. Ccr2 deﬁciency also
attenuated HFD-induced weight gain by causing a reduction
in caloric intake, highlighting the possible involvement of
Ccr2 in the control of eating behavior. Furthermore, treatment
of obese mice with a pharmacological antagonist of Ccr2 led to
decreased adipose tissue macrophage inﬁltration and improved
insulin sensitivity [47].
Complementary studies on the Ccr2 ligand, Mcp1, have
shown that its expression is increased in obese mice, suggesting
that changes in Mcp1 levels promote the recruitment of macro-
phages to adipose tissue which then causes inﬂammation and
insulin resistance. This hypothesis has been tested in transgenic
mice that overexpress Mcp1 under the control of the adipose
tissue-speciﬁc AP2 promoter. This study found that overex-
pression of Mcp1 in adipose tissue can enhance macrophage
inﬁltration and cause insulin resistance [48,49]. Kanda et al.
went further to show that the onset of these abnormalities in
obese mice could be prevented by genetic deletion of Mcp1
[48]. Recently, Inouye et al. suggest that Mcp1 may also have
a role in energy metabolism. However, in contrast to previous
studies, they showed that HFD-fed Mcp1 KO mice developed
hyperinsulinemia and increased adiposity independent of adi-
pose tissue macrophage levels, which were unchanged. Diﬀer-
ences in experimental approaches as well as the complexity/
redundancy of chemokine signaling may account for these con-
ﬂicting conclusions [50]. Taken together, the bulk of the evi-
dence suggests that the Mcp1/Ccr2 axis could provide one
mechanistic link between obesity, adipose tissue inﬂammation
and insulin resistance.3.9. The dynamic inﬂammatory properties of adipose tissue
macrophages
Recent studies by Lumeng et al. showed that adipose tissue
macrophages have heterogeneous inﬂammatory properties that
are inﬂuenced by diet and obesity. They showed diﬀerences in
the inﬂammatory properties of resident adipose tissue macro-
phage versus macrophages that are recruited to adipose tissue
in obesity. In vivo macrophage pulse labeling studies showed
that newly recruited adipose tissuemacrophages are pro-inﬂam-
matory, as indicated by increased expression of Il6, Nos2 and
Ccr2, while resident adipose tissue macrophages are anti-
inﬂammatory. This diﬀerence in inﬂammatory phenotype re-
quires an intact Mcp1/Ccr2 axis because resident macrophages
in lean adipose tissue originate from aCCR2CX3CR1himono-
cyte pool, whereas recruited pro-inﬂammatory adipose tissue
macrophages originate from a pool of CCR2+CX3CR1low
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receptor 1 (CX3CR1), is a fractalkine receptor that mediates
cell-adhesive and migratory functions on monocytes in inﬂam-
mation.
Further studies showed that macrophages are also capable
of undergoing a phenotypic switch from an M1 state, which
was deﬁned as the ‘‘classically activated’’ pro-inﬂammatory
macrophage, to the M2 state or the ‘‘alternatively activated’’
non-inﬂammatory cell. The M2 classiﬁcation involves cells
that express arginase and the anti-inﬂammatory cytokine Il-
10 and have a high capacity to repair damaged tissue [52].
M1 cells express inﬂammatory cytokines and the cell surface
marker Cd11c [41,53]. Adipose tissue from obese mice contains
proportionately more M1 macrophages, whereas, lean adipose
tissue contains more M2 macrophages, and increased M1 con-
tent positively correlates with inﬂammation, macrophage
inﬁltration and insulin resistance. The authors propose a
mechanism for how a macrophage phenotypic switch occurs
in obesity. In their model, obesity causes changes in circulating
monocytes that become Ly-6ChiCCR2+ ‘‘inﬂammation-
primed’’ monocytes predisposing them toward an M1 conver-
sion in tissue. When these macrophages enter obese adipose
tissue, local environmental cues cause these pre-M1 macro-
phages to fully convert to the M1 state [41]. It is probable that
local concentrations of inﬂammatory mediators, such as
FFAs, Tnf or other cytokines/adipokines contribute to this
polarity switch.3.10. Cbl-associated protein
Recent ﬁndings have shown that Cbl-associated protein
(CAP), known as a positive regulator of glucose transport into
cells, plays a role in obesity-related inﬂammation due to its
function in maintaining normal macrophage activity [13].
Cap knockout mice (Sorbs1/) are protected from high fat
diet-induced insulin resistance because of decreased adipose
tissue macrophage content and reduced inﬂammation.
Sorbs1/ mice show reduced activity of both Ikkb and Jnk,
decreased Mcp1 protein levels, reduced macrophage inﬁltra-
tion and lower white blood cell counts. Furthermore, elicited
macrophages from Sorbs1/ mice exhibit decreased mobility
when measured in vitro. By using bone marrow transplanta-
tion (BMT) to achieve adoptive transfer of myeloid cells, these
investigators showed that this insulin sensitive phenotype was
transferred to wildtype obese mice that were transplanted with
bone marrow from Sorbs1/ mice. This study further high-
lights the importance of macrophages in the development of
obesity-induced inﬂammation and insulin resistance, showing
that normal macrophage function is necessary for the develop-
ment of HFD/obesity-induced insulin resistance [54].3.11. Macrophage-peroxisome proliferator activated receptor-
gamma (Pparg)
Pparg is a nuclear receptor required for adipogenesis. It is
also the target for the insulin-sensitizing TZD class of drugs,
which promote adipogenesis and cause systemic insulin sensi-
tivity. In addition to adipocytes, Pparg is also expressed in
macrophages where it negatively regulates a large set of inﬂam-
matory pathway genes by a unique transrepression mecha-
nism. Based on this concept, deletion of Pparg from
macrophages should derepress the inﬂammatory program,
and indeed Hevener et al showed that myeloid-speciﬁc deletionof Pparg (Mac-Pparg-KO) results in inﬂammatory pathway
activation with the development of skeletal muscle and hepatic
insulin resistance in lean C57/Bl6 mice fed a normal diet. The
relative degree of insulin resistance became more severe when
these mice where subjected to HFD compared to HFD-fed
controls. Interestingly, the ability of TZD treatment to im-
prove insulin sensitivity was attenuated in these animals, indi-
cating that the anti-inﬂammatory properties of TZDs in tissue-
resident macrophages are a component of their insulin-sensi-
tizing eﬀects [55].
In a similar study, myeloid deletion of Pparg in BALB/c
mice resulted in insulin resistance and glucose intolerance. It
was also shown that myeloid Pparg is required for the alterna-
tive activation of macrophages. As a result, these mice had a
reduction in the total number of adipose tissue macrophages
but increased local inﬂammation due to the absence of M2
macrophages. This study suggests a potential beneﬁcial role
of alternatively activated macrophages in protecting against
obesity-induced insulin resistance [52].3.12. Macrophage Jnk1
As discussed previously, Jnk1 is an important component of
obesity-induced insulin resistance. Due to its apparent role in
the development of obesity, it is necessary to separate the roles
of Jnk1 in adiposity versus inﬂammation. In a recently com-
pleted study, Solinas et al. generated mice with Jnk1-deﬁcient
macrophages by transplanting donor Jnk1/ bone marrow
into Jnk1+/+ recipient mice. These mice became obese when
placed on HFD but were more insulin sensitive and had re-
duced inﬂammatory markers compared to control, Jnk1+/+
mice transplanted with Jnk1+/+ bone marrow. Chemotaxis as-
says showed that Jnk1/ primary macrophages exhibited an
impaired ability to migrate down a chemotactic gradient.
Additionally, ‘‘reverse chimeras’’, i.e. wildtype donor bone
marrow transplanted into recipient Jnk1/ mice, manifested
an improvement in glucose homeostasis as well as resistance
to diet-induced obesity [56]. Taken together, these ﬁndings
demonstrate that: (1) Jnk1 signaling in macrophages is a key
component of macrophage function and a mediator of the
macrophage inﬂammatory response which ultimately leads to
insulin resistance, and (2) Jnk1 also plays an important role
in non-hematopoietic cells in the development of obesity and
the associated insulin resistance.3.13. Obesity-induced cellular events leading to inﬂammation
The above studies have largely focused on the eﬀectors of the
inﬂammatory program, but not on the underlying causes,
which initiate the pro-inﬂammatory state. For example, Tnf
and other cytokines/chemokines are symptomatic of inﬂamma-
tion, and while they propagate and/or maintain the inﬂamma-
tory state, they are not the initial cause(s) of inﬂammation.
Determining the local environmental cues that ignite the initial
inﬂammatory response is important to our understanding of
the root mechanisms of obesity-induced inﬂammation and
insulin resistance. The next section focus on advances made
to identify causes of chronic inﬂammation in metabolic disor-
ders.3.14. FFA stimulation of Toll-like receptor 4
Tlr4 belongs to the family of Toll-like receptors that
function as pattern recognition receptors that guard against
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tem. These receptors recognize/sense bacterial and viral com-
ponents and respond by activating innate immunity
pathways. Tlr4, in particular, is stimulated by lipopolysaccha-
ride (LPS), an endotoxin released by gram-negative bacteria.
Tlr4 stimulation results in the activation of both Ikkb/NFjB
and JNK/AP-1 signaling, culminating in the expression and
secretion of pro-inﬂammatory cytokines/chemokines, includ-
ing, Il1b, IL-6, Tnf, Mcp1, etc. (reviewed in [57]).
The role of Tlr4 as a key component in fatty acid-induced
inﬂammation was ﬁrst identiﬁed in studies examining the abil-
ity of dietary fatty acids to activate the inﬂammatory response
via Tlr4 signaling in cultured macrophages (reviewed in [58]).
The link between Tlr4 and fatty acid and obesity-induced
insulin resistance was recently further assessed by Shi et al.
This study found that FFA activate the NFkB signaling path-
way in primary macrophages from wildtype mice but not in
macrophages derived from Tlr4 deﬁcient (Tlr4/) mice. In
addition, they demonstrated that saturated fatty acids are
the most potent inducers of this inﬂammatory response. In
in vivo studies, they found that obese mice have increased
Tlr4 expression in adipose tissue compared to lean controls.
Furthermore, male Tlr4/ mice are protected from lipid infu-
sion-induced insulin resistance, presumably due to decreased
FFA-induced NFjB transcriptional activity, as well as reduced
expression of Tnf, Il6 and Mcp1 expression in adipose tissue.
They also show that obese female Tlr4/ mice are partially
protected from insulin resistance due to decreased inﬂamma-
tion in both liver and adipose tissue. This work implicates
Tlr4 in the development of lipid and obesity-induced insulin
resistance and suggests that Tlr4 can act as a potential sensor
of elevated tissue and/or serum FFA concentrations that are
commonly associated with obesity [59].
The study by Shi et al. implicates Tlr4 in the inﬂammation/
insulin resistance process, but do not elucidate the speciﬁc tis-
sues in which Tlr4 depletion functions to protect mice from
insulin resistance. Recent progress has been made on the latter
question by use of bone marrow transplantation to create chi-
meric mice in which Tlr4 is depleted from the myeloid com-
partment. Thus, wt mice reconstituted with bone marrow
from Tlr4/ mice represent a functional macrophage knock-
out model, and these animals are protected from the eﬀects
of HFD and obesity to produce insulin resistance. Expression
analysis in these mice showed a signiﬁcant reduction in hepatic
Ccl5 (also known as RANTES) and Tnf levels, indicating re-
duced inﬂammation, despite pronounced hepatic steatosis
[60]. This suggests that Kupﬀer cells, known to be activated
in hepatic steatosis, can mediate inﬂammatory responses via
Tlr4 signaling (reviewed in [61]). These results indicate that
Tlr4 in macrophages and Kupﬀer cells participates in a sensing
mechanism facilitating fatty acid-induced inﬂammation and
insulin resistance.3.15. Endoplasmic reticulum stress
Another potential cause of inﬂammation in obesity is endo-
plasmic reticulum (ER) stress. This idea holds that overnutri-
tion causes mechanical stress, excess lipid accumulation and
protein synthesis, and abnormal energy metabolism all of
which lead to an overburdened ER. This heightened synthetic
state in the ER disrupts the normal folding of proteins and
activates the unfolded protein response (UPR) that is knownto induce stress response pathways. For example, O¨zcan
et al. have shown the induction of ER stress induces insulin
resistance via JNK-mediated serine phosphorylation of IRS1
in cultured liver cells. Furthermore they demonstrated that ob-
ese mice deﬁcient for one allele of X-box binding protein-1
(XBP1), a transcription factor that promotes expression of
molecular chaperones in response to ER stress, are more se-
verely insulin resistant compared to obese controls. These mice
exhibit ER stress, increased JNK activity and IRS1 serine
phosphorylation [62]. This same group has also reported that
oral administration of active chemical chaperones reduce ER
stress and improves glucose homeostasis in obese mice [63].4. Conclusion
Insulin resistance is a complex metabolic defect that most
likely has several etiologies dependent on the pathophysiologic
state. In humans, there is a genetic component to decreased
insulin sensitivity in patients with T2DM and it has been sug-
gested that inherited defects in mitochondrial function with a
decreased capacity to oxidize fatty acids is a contributory fac-
tor [64]. In addition, obesity is a major cause of insulin resis-
tance in T2DM and recent information demonstrates that
chronic, low-grade inﬂammation associated with obesity is
an important etiologic mechanism in decreasing insulin signal-
ing. In this regard, inﬂammation causes cell autonomous insu-
lin resistance in muscle, liver and adipose cells and activated
tissue macrophages can underlie tissue-autonomous inﬂamma-
tory processes. What remains to be deﬁned, however, is the se-
quence of events by which obesity initiates this cascade, and
which tissue(s) are the primary eﬀectors in this process versus
those that are secondarily involved. Based on the evidence
summarized in this review, we highlight a process of gradual
progression to insulin resistance in obese states. In this model,
obesity causes excessive growth of adipose depots with adipo-
cyte hypertrophy and hyperplasia. This fat overload results in
the activation of stress/inﬂammatory pathways and subsequent
paracrine/autocrine-mediated cellular insulin resistance. This
in turn increases adipocyte FFA release which stimulates resi-
dent macrophages and adipocytes, at least partly through Toll-
like receptors, causing increased expression of Tnf, Mcp1 and
other pro-inﬂammatory cytokines. Additionally, these hyper-
trophied unstable adipocytes eventually die and release their
lipid content causing additional migration of macrophages to
clear dead or dying adipocytes. The resulting internal environ-
ment of this adipose tissue is lipotoxic and pro-inﬂammatory,
favoring the M2 to M1 conversion of resident macrophages or
of newly recruited Ly-6ChiCCR2+ ‘‘inﬂammation-primed’’
monocytes. All of these events culminate in adipose tissue
inﬂammation and insulin resistance. This can be envisioned
as a two step process in which the inﬂammatory pathway is
activated in a tissue resident macrophage which leads to para-
crine activation of inﬂammatory pathway components in
neighboring insulin target cells, causing impaired insulin sig-
naling. The resulting eﬄux of FFA and increased secretion
of cytokines can lead to secondary insulin resistance in other
tissues.
In addition to inﬂammation and insulin resistance within
adipose tissue, the same process most likely occurs in the liver.
Thus, the liver contains a large pool of tissue-resident macro-
phages, (i.e. Kupﬀer cells) and disabling the inﬂammatory
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[65]. There may be similarities in the triggers for hepatic
inﬂammation, since increased lipid content and steatosis are
common ﬁndings in insulin resistant states. Such inﬂammation
in the liver, besides causing localized insulin resistance, would
also contribute to systemic inﬂammation and secondary insu-
lin resistance in other tissues, such as skeletal muscle.
Although chronic inﬂammation can cause skeletal muscle
insulin resistance, the precise sequence and the connections be-
tween inﬂammation and decreased insulin signaling in myo-
cytes remains poorly elucidated. It is possible that increased
circulating FFAs or altered cytokine/adipokine levels cause
secondary insulin resistance in muscle. Extramyocellular adi-
pose deposits could also contribute to this process in a para-
crine fashion. Finally, increased macrophage content has
been reported in insulin resistant muscle, raising the possibility
of macrophage-mediated tissue autonomous insulin resistance,
as in liver and fat [66,67]. Of course, these possibilities are not
mutually exclusive.
Clearly, much progress has been made in this area in recent
years, and it is now clear that chronic low-grade tissue inﬂam-
mation is an important contributor to the etiology of obesity
and high fat diet-induced insulin resistance. Resident tissue
macrophages play a key role in orchestrating this tissue inﬂam-
matory response, and future studies will undoubtedly shed
much light on the underlying mechanisms.
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